Organovo Holdings, Inc. (NASDAQ:ONVO) Short Interest Down 22.2% in November

Organovo Holdings, Inc. (NASDAQ:ONVO) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 106,300 shares, a drop of 22.2% from the November 15th total of 136,600 shares. Based on an average trading volume of 140,100 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Trading of Organovo

A hedge fund recently bought a new stake in Organovo stock. Armistice Capital LLC acquired a new stake in Organovo Holdings, Inc. (NASDAQ:ONVO) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 929,000 shares of the medical research company’s stock, valued at approximately $708,000. Armistice Capital LLC owned approximately 6.46% of Organovo at the end of the most recent reporting period. 8.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Organovo in a research report on Friday. They set a “sell” rating for the company.

Organovo Stock Down 3.1 %

ONVO stock traded down $0.01 during trading on Monday, hitting $0.39. 73,073 shares of the company traded hands, compared to its average volume of 361,092. The stock’s 50-day simple moving average is $0.43 and its 200 day simple moving average is $0.57. Organovo has a 1 year low of $0.32 and a 1 year high of $1.74.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.